Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 7, 1997, Pages 287-295

  Brynne, N ^a   Stahl, M M S ^b   Hallen B ^a   Edlund, P O ^a   Palmer L ^a   Hoglund P ^b   Gabrielsson, J ^c  

^a PFIZER INC   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Active metabolite; Healthy volunteers; Mass balance; Pharmacokinetics; Tolterodine

Indexed keywords

DRUG METABOLITE; MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEALKYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICTURITION DISORDER; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; SALIVATION; XEROSTOMIA;

ADULT; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; REFERENCE VALUES; URINARY BLADDER DISEASES;

EID: 0030860061     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Andersson K-E 1993 The pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45: 253-308
2. Bertilsson L 1995 Geographical/interracial differences in polymorphic drug oxidation - Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29: 192-209
3. Blaivas JG, Labib KB, Michalik J, Zayed AAH 1980 Cystometric response to prophanteline in detrusor hyperreflexia: therapeutic implications. J Urol 124: 259-262
4. Cardozo LD, Cooper D, Versi E 1987 Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 6: 256-257
5. Davies SS, Hardy JG, Fara JW 1986 Transit of pharmaceutical dosage forms in the small intestine. Gut 27: 886-892
6. Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, Clare RA, Murray S 1976 Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19: 11-15
7. Gibaldi M, Perrier D 1982 Pharmacokinetics (2nd ed). Dekker, New York
8. Gillberg P-G, Modiri A-R, Sparf B 1994 Tolterodine - a new agent with tissue effect selectivity for urinary bladder. Neurourol Urodyn 13: 435-436
9. Naerger H, Fry CH, Nilvebrant L 1995 Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders. Neurourol Urodyn 14: 524-526
10. Nilvebrant L, Glas G, Jönsson Å, Sparf B 1994 The in vitro pharmacological profile of tolterodine - a new agent for the treatment of urinary urge incontinence. Neurourol Urodyn 13: 433-435
11. Nilvebrant L, Sundquist S, Gillberg P-G 1996 Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn 15: 310-311
12. Rowland M, Tozer TN 1995 Clinical pharmacokinetics: concepts and applications (3rd ed). Williams and Wilkins, London
13. Stahl MMS, Ekström B, Sparf B, Mattiasson A, Andersson K-E 1995 Urodynamic and other effects of tolterodine - a novel antimuscarinic drug for treatment of detrusor overactivity. Neurourol Urodyn 14: 647-655
14. Statîstical Consultants Inc: 1986 Pcnonlin and nonlin84: Software for the statistical analysis of nonlinear models. Am Statistician 40: 52
15. Sundwall A, Vessman J, Strindberg B 1973 Fate of emepronium bromide in man in relation to its pharmacological effects. Eur J Clin Pharmacol 6: 191-195
16. Ulmsten U, Andersson K-E 1977 The effects of emeprone on intravesical and intra-urethral pressures in women with urgency incontinence. Scand J Urol Nephrol 11: 103-109
17. Vose CW, Ford GC, Grigson SJW, Haskins NJ, Prout M 1981 Pharmacokinetics of propantheline bromide in normal man. Br J Urol 126: 81-85
18. Yarker YE, Goa KL, Fitton A 1995 Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Aging 6: 243-262